Subscribe

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

INR1,942.60 +21.20 (+1.10%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address Sun House 400063
Mumbai, IN
CEO Dilip Shantilal Shanghvi
Website sunpharma.com
IPO 1996-01-01
ISIN INE044A01036

Explore sections of this company profile

Also trades on Bombay Stock Exchange · SUNPHARMA.BO (INR) National Stock Exchange of India · SUNPHARMA.NS (INR)
Description

Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
INR1,942.60 +21.20 (+1.10%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
0.08
Float Shares
1.07B
Free Float %
44.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-2.71% -2.03% +13.55% +6.25% +3.32% +7.00% +9.78% +93.25% +166.30% +138.25% +102,122.22%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1,942.60
DCF (Unlevered) 4,805.57 +147.4%
DCF (Levered) 6,033.77 +210.6%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 91% Bullish
Rating 2026-05 Change
Strong Buy 7 -2
Buy 23 0
Hold 0 0
Sell 1 -1
Strong Sell 2 0
Quality scores
Altman Z-Score
12.10
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +11.2% ★ Q1'26: +12.8% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +4.8% Q1'26: +25.6% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +14.4% Q1'26: +16.4% (vs Q1'25)
  • ✓
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +23.2% ★ Q1'26: +18.8% (vs Q1'25)
  • ✓
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +18.5% ★ Q1'26: +15.1% (vs Q1'25)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.2% Q1'26: +0.5% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    0.34× ★ Q1'26: 0.42× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.10) × ERP
WACC = 99% × Ke + 1% × Kd (7.4%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 4,805.49 Current price: 1,942.60
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2011
actual 		Mar 2012
actual 		Mar 2013
actual 		Mar 2014
actual 		Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
34 Rev. Ana.
25 EPS Ana. 		Mar 2027
27 Rev. Ana.
25 EPS Ana. 		Mar 2028
30 Rev. Ana.
27 EPS Ana. 		Mar 2029
2 Rev. Ana.
3 EPS Ana. 		Mar 2030
1 Rev. Ana.
1 EPS Ana.
Revenue
57.21B
est: 57.65B (-0.8%)
80.01B
est: 77.97B (+2.6%)
113.00B
est: 111.96B (+0.9%)
160.80B
est: 162.57B (-1.1%)
273.92B
est: 181.28B (+51.1%)
281.09B
est: 282.21B (-0.4%)
313.08B
est: 317.54B (-1.4%)
264.16B
est: 264.59B (-0.2%)
290.66B
est: 295.22B (-1.5%)
328.38B
est: 325.87B (+0.8%)
334.98B
est: 338.58B (-1.1%)
386.54B
est: 387.26B (-0.2%)
438.86B
est: 436.96B (+0.4%)
484.97B
est: 492.09B (-1.4%)
525.78B
est: 527.16B (-0.3%)
582.22B
570.44B – 588.54B
+10.4% YoY
648.82B
634.81B – 667.16B
+11.4% YoY
722.96B
679.84B – 789.70B
+11.4% YoY
837.06B
823.91B – 850.22B
+15.8% YoY
914.48B
876.41B – 971.18B
+9.2% YoY
EBITDA
22.98B
est: 23.80B (-3.5%)
36.76B
est: 30.87B (+19.1%)
52.31B
est: 51.40B (+1.8%)
74.56B
est: 63.88B (+16.7%)
81.35B
est: 51.44B (+58.1%)
85.48B
est: 98.70B (-13.4%)
98.13B
est: 74.15B (+32.3%)
55.68B
est: 82.38B (-32.4%)
64.60B
est: 46.73B (+38.2%)
68.57B
est: 56.02B (+22.4%)
83.45B
est: 71.78B (+16.3%)
101.54B
est: 79.35B (+28.0%)
116.51B
est: 86.47B (+34.7%)
128.76B
est: 128.94B (-0.1%)
149.68B
est: 138.22B (+8.3%)
152.56B
149.48B – 154.22B
+10.4% YoY
170.01B
166.34B – 174.82B
+11.4% YoY
189.44B
178.14B – 206.93B
+11.4% YoY
219.34B
215.89B – 222.79B
+15.8% YoY
239.63B
229.65B – 254.48B
+9.2% YoY
EBIT
20.94B
est: 17.10B (+22.4%)
33.85B
est: 23.91B (+41.6%)
48.95B
est: 42.48B (+15.2%)
70.47B
est: 58.89B (+19.7%)
69.66B
est: 48.71B (+43.0%)
75.39B
est: 100.80B (-25.2%)
85.72B
est: 82.98B (+3.3%)
40.90B
est: 71.98B (-43.2%)
47.37B
est: 36.69B (+29.1%)
49.48B
est: 40.77B (+21.4%)
64.28B
est: 50.60B (+27.0%)
81.56B
est: 55.94B (+45.8%)
93.06B
est: 60.96B (+52.6%)
105.20B
est: 130.59B (-19.4%)
126.05B
est: 139.99B (-10.0%)
154.51B
151.38B – 156.19B
+10.4% YoY
172.18B
168.46B – 177.05B
+11.4% YoY
191.86B
180.42B – 209.57B
+11.4% YoY
222.14B
218.65B – 225.63B
+15.8% YoY
242.68B
232.58B – 257.73B
+9.2% YoY
Net Income
18.16B
est: 18.99B (-4.4%)
25.87B
est: 24.56B (+5.3%)
29.83B
est: 36.80B (-18.9%)
31.41B
est: 43.31B (-27.5%)
45.39B
est: 35.77B (+26.9%)
47.16B
est: 69.53B (-32.2%)
69.64B
est: 54.87B (+26.9%)
21.62B
est: 58.11B (-62.8%)
26.65B
est: 22.73B (+17.3%)
37.65B
est: 29.46B (+27.8%)
29.04B
est: 39.95B (-27.3%)
32.73B
est: 44.17B (-25.9%)
84.74B
est: 48.13B (+76.1%)
95.76B
est: 103.89B (-7.8%)
109.29B
est: 119.66B (-8.7%)
114.79B
108.93B – 133.38B
-4.1% YoY
135.80B
124.24B – 145.01B
+18.3% YoY
157.07B
136.02B – 185.72B
+15.7% YoY
199.19B
186.68B – 211.70B
+26.8% YoY
203.65B
192.63B – 220.06B
+2.2% YoY
SGA
—
est: 16.84B (-100.0%)
10.40B
est: 24.81B (-58.1%)
30.51B
est: 37.00B (-17.5%)
44.04B
est: 49.69B (-11.4%)
46.48B
est: 62.71B (-25.9%)
49.08B
est: 161.83B (-69.7%)
50.28B
est: 134.27B (-62.5%)
54.81B
est: 92.09B (-40.5%)
61.03B
est: 120.65B (-49.4%)
63.99B
est: 137.40B (-53.4%)
69.04B
est: 154.86B (-55.4%)
73.54B
est: 171.20B (-57.0%)
83.55B
est: 186.56B (-55.2%)
95.02B
est: 101.71B (-6.6%)
100.51B
est: 109.03B (-7.8%)
120.34B
117.90B – 121.65B
+10.4% YoY
134.10B
131.21B – 137.90B
+11.4% YoY
149.43B
140.52B – 163.22B
+11.4% YoY
173.01B
170.29B – 175.73B
+15.8% YoY
189.01B
181.15B – 200.73B
+9.2% YoY
EPS
8.75
est: 8.39 (+4.3%)
12.85
est: 11.37 (+13.0%)
14.40
est: 15.78 (-8.7%)
15.20
est: 25.88 (-41.3%)
18.90
est: 28.83 (-34.4%)
18.90
est: 22.29 (-15.2%)
29.00
est: 29.84 (-2.8%)
9.01
est: 12.30 (-26.7%)
11.11
est: 16.27 (-31.7%)
15.69
est: 17.98 (-12.7%)
12.10
est: 24.94 (-51.5%)
13.64
est: 31.99 (-57.4%)
35.32
est: 35.12 (+0.6%)
39.91
est: 43.32 (-7.9%)
45.60
est: 49.18 (-7.3%)
49.90
45.36 – 55.54
+1.5% YoY
56.51
51.73 – 60.38
+13.2% YoY
67.46
56.64 – 77.33
+19.4% YoY
83.36
77.73 – 88.15
+23.6% YoY
84.80
80.21 – 91.63
+1.7% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-22 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-21 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-20 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-19 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-18 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-15 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-14 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-13 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-12 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-11 C- 1/5 4/5 1/5 1/5 1/5 1/5 1/5
2026-05-08 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-05-07 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-05-06 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-05-05 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-05-04 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-30 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-29 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-28 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-27 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-24 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-23 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-22 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-21 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-20 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-17 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-16 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5
2026-04-15 C 2/5 4/5 1/5 1/5 1/5 2/5 1/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
12.73B
OE per share TTM
5.32
Owner's Yield
0.29%
Maintenance CapEx ratio
13.64%
Maint CapEx / Avg PPE
25.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
3.15M
Shares Outstanding
2.40B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Aalok Dilip Shanghvi Chief Operating Officer, Head of Global Generics R&D, Business Devp., and Whole Time Director 76M male
Kalyanasundaram Subramanian Director of Corporate Development 65M male
Dilip Shantilal Shanghvi Executive Chairman of the Board 65M male
Dheeraj Prasad Sinha EVP & Chief Information Officer — male
Jayashree Satagopan Executive Vice President & Chief Financial Officer — female
Kirti Wardhaman Ganorkar Managing Director — male
Sana Shaikh Head of Marketing — female
Suresh Rai Chief Human Resources Officer — male
Abhishek Sharma Vice President, Head of Investor Relations & Strategic Projects — —
Anoop Deshpande Company Secretary & Compliance Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic